Literature DB >> 17649775

High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women.

Andrea Gingelmaier1, Thomas Grubert, Ralph Kaestner, Ioannis Mylonas, Tobias Weissenbacher, Florian Bergauer, Lisa Barthell, Klaus Friese.   

Abstract

AIM: A) evaluation of the recurrence of cervical dysplasia after surgical treatment and of the rate of HPV persistence of HIV-infected women and b) the influence of antiretroviral therapy on the recurrence. PATIENTS AND METHODS: In a retrospective analysis, the follow-up data of HIV-positive women visiting our outpatient clinic regarding results of cervical cytology, cervical HPV detection, cervical biopsy, patient history of dysplasia and antiretroviral therapy were assessed. A total of 388 HIV-positive women had a mean follow-up of 2.7 years and a median of 2.5 outpatient visits.
RESULTS: Out of the 344 patients (57.3%) tested for HPV, 197 showed at least one positive HPV result. Of the same group, 136 women had four or more HPV tests which showed that 84 of them (61.8%) had a persistent HPV-infection. Overall, 157/388 had cervical dysplasia and 70 needed surgery. Forty-one of the 70 patients (58.6%) received more than one surgical treatment because of a recurrence, all of this group had persistent HPV. DISCUSSION: The recurrence of cervical dysplasia in HIV-positive women after surgical treatment was found to be very high as was the associated long-term persistence of HPV-infection. HPV persistence represented an excellent marker for relapsing cervical dysplasia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17649775

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Authors:  Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

2.  Prevalence and correlates of genital warts in Kenyan female sex workers.

Authors:  Barbara E Kavanaugh; Katherine Odem-Davis; Walter Jaoko; Benson Estambale; James N Kiarie; Linnet N Masese; Ruth Deya; Lisa E Manhart; Susan M Graham; Raymond Scott McClelland
Journal:  Sex Transm Dis       Date:  2012-11       Impact factor: 2.830

3.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.

Authors:  Lara F Bratcher; Vikrant V Sahasrabuddhe
Journal:  Infect Agent Cancer       Date:  2010-05-12       Impact factor: 2.965

4.  Lamin A/C deficiency is an independent risk factor for cervical cancer.

Authors:  Callinice D Capo-chichi; Blanche Aguida; Nicodème W Chabi; Qi K Cai; Georges Offrin; Vidéhouénou K Agossou; Ambaliou Sanni; Xiang-Xi Xu
Journal:  Cell Oncol (Dordr)       Date:  2015-11-04       Impact factor: 6.730

5.  Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya.

Authors:  Hugo De Vuyst; Nelly R Mugo; Silvia Franceschi; Kevin McKenzie; Vanessa Tenet; Julia Njoroge; Farzana S Rana; Samah R Sakr; Peter J F Snijders; Michael H Chung
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

6.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

7.  Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus-infected Women: A Systematic Review and Meta-analysis of Treatment Failure.

Authors:  Pierre Debeaudrap; Joelle Sobngwi; Pierre-Marie Tebeu; Gary M Clifford
Journal:  Clin Infect Dis       Date:  2019-10-15       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.